Refine by
Emas Articles & Analysis
152 news found
Introduction In today’s safety-focused global environment, manufacturers need technologies that not only meet compliance standards but also improve performance, efficiency, and reliability. Whether it’s a cleanroom in a pharmaceutical facility or a high-heat chamber in additive manufacturing, accurate gas analysis plays a crucial role. Cambridge Sensotec’s SIL2 compliant ...
The EU Active Substance Master File (ASMF) is a technical document containing confidential information on an API that is submitted by the manufacturer of the API to the EMA or the medicines regulatory authority of an EU member state. As a form of DMF in the EU, the ASMF is used to support MAA or MAV by manufacturers of pharmaceutical preparations for human or veterinary use. ...
The expert team at Proregulations is skilled at preparing the modules of the MAA document in compliance with EMA guidelines, as well as conducting a comprehensive review and gap analysis of the document. ...
We’re excited to announce that ESdat Environmental Data Management Software is the Gold Sponsor for the BCEIA & EMA of BC Emerging Professionals Social on November 20, 2024!This event is a fantastic opportunity for young professionals to connect, share insights, and learn more about the latest developments in environmental management. ...
Genotoxic impurity analysis is a critical aspect of pharmaceutical development and manufacturing, as regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent guidelines in place to ensure the safety of pharmaceutical products. ...
Aiming at intelligent manufacturing, high efficiency and eco system, and a quality system to be certified by the US FDA, EU EMA and China NMPA, the peptide production facility includes a R&D center, a pilot plant, production lines, and business center. ...
Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with comparable visual acuity as well as rapid and resilient fluid control to the ...
ByBayer AG
The Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA). Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies: ELEVATE (NCT05563220); ELECTRA (NCT05386108); ELONA (NCT05618613); ELCIN (NCT05596409). ...
This certification was granted following a successful inspection by the Spanish Agency for Medicines and Medical Devices (AEMPS), a part of the European Medicines Agency (EMA) network. The company now operates two facilities in San Sebastian, Spain, with seven state-of-the-art single-use suites that have up to 2,000 liters of manufacturing capacity, making it a world-leading ...
ByBayer AG
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. ...
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
ByBayer AG
This meets the requirements of both the US and EU regulators – the FDA and EMA. After a detailed review, the Company has decided that the Phase 3 programme should consist of two Phase 3 studies including patients in two well-defined surgery models. ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. ...
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness Bayer will apply for a patent term extension for the patent covering aflibercept, the active ingredient in Eylea™, of six months once the European Commission adopts a decision for a label extension ...
ByBayer AG
Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in Switzerland Article 20 ...
GMP Manufacturing Alfa Chemistry provides MCB, WCB, and EOPCB banking services in compliance with European EMA and Chinese NMPA GMP regulatory requirements. In addition, the company is capable of conducting GMP manufacturing at scales ranging from 50 L, 200 L, 500 L, 1,000 L, to 2,000 L for cell culture, linkers, payloads, and complete ADCs. ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
It was also approved by the European Medicines Agency (EMA) for the treatment of PH1 in all age groups. The Committee for Medicinal Products for Human Use (CHMP) of the EMA delivered a positive opinion recommending variation to the marketing authorization of OXLUMO based on ILLUMINATE-C data from patients with advanced PH1 in September 2022. ...
In March 2022, Bayer submitted a Type II Variation application based on the data from FIGARO-DKD to the European Medicines Agency (EMA) to seek an extension of the marketing authorization for Kerendia™ to include early stages of CKD associated with T2D. ...
ByBayer AG
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, ...